399 related articles for article (PubMed ID: 29948463)
1. Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.
Naito T; Osaki M; Ubano M; Kanzaki M; Uesaka Y
Neurol Sci; 2018 Oct; 39(10):1791-1793. PubMed ID: 29948463
[No Abstract] [Full Text] [Related]
2. Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report.
Pomerantz M; Lichtenstein DA; Niesvizky-Kogan I; Sohal R; Leibovitch J; Basnet A
J Immunother; 2019; 42(9):348-349. PubMed ID: 31261166
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung.
Matsuoka H; Kimura H; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
Clin Lung Cancer; 2018 Sep; 19(5):e597-e599. PubMed ID: 29857970
[No Abstract] [Full Text] [Related]
4. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
Ito M; Fujiwara S; Fujimoto D; Mori R; Yoshimura H; Hata A; Kohara N; Tomii K
Ann Oncol; 2017 Sep; 28(9):2318-2319. PubMed ID: 28911080
[No Abstract] [Full Text] [Related]
5. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
6. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
7. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J
N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473
[No Abstract] [Full Text] [Related]
8. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
10. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
[No Abstract] [Full Text] [Related]
11. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
12. Nivolumab plus ipilimumab in metastatic colorectal cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
[No Abstract] [Full Text] [Related]
13. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
14. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
15. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
16. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
Galmiche S; Lheure C; Kramkimel N; Franck N; Boitier F; Dupin N; Turc G; Psimaras D; Aractingi S; Guégan S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e440-e443. PubMed ID: 31219194
[No Abstract] [Full Text] [Related]
17. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
Cope S; Keeping ST; Goldgrub R; Ayers D; Jansen JP; Penrod JR; Korytowsky B; Juarez-Garcia A; Yuan Y
J Comp Eff Res; 2019 Jul; 8(10):733-751. PubMed ID: 31237143
[No Abstract] [Full Text] [Related]
19. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern.
Redondo B; Moliz C; Alonso M; Paz-Ares L; Praga M; Morales E
Nefrologia (Engl Ed); 2019; 39(1):94-96. PubMed ID: 29941195
[No Abstract] [Full Text] [Related]
[Next] [New Search]